- Home
- OUST vs TSHA Comparison
OUST vs TSHA Comparison
Compare OUST & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OUST
- TSHA
- Stock Information
- Founded
- OUST 2015
- TSHA 2019
- Country
- OUST United States
- TSHA United States
- Employees
- OUST N/A
- TSHA N/A
- Industry
- OUST Industrial Machinery/Components
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- OUST Technology
- TSHA Health Care
- Exchange
- OUST Nasdaq
- TSHA Nasdaq
- Market Cap
- OUST 444.3M
- TSHA 397.8M
- IPO Year
- OUST N/A
- TSHA 2020
- Fundamental
- Price
- OUST $12.23
- TSHA $2.71
- Analyst Decision
- OUST Strong Buy
- TSHA Strong Buy
- Analyst Count
- OUST 7
- TSHA 7
- Target Price
- OUST $14.24
- TSHA $7.00
- AVG Volume (30 Days)
- OUST 1.8M
- TSHA 5.2M
- Earning Date
- OUST 05-08-2025
- TSHA 05-15-2025
- Dividend Yield
- OUST N/A
- TSHA N/A
- EPS Growth
- OUST N/A
- TSHA N/A
- EPS
- OUST N/A
- TSHA N/A
- Revenue
- OUST $117,789,000.00
- TSHA $7,224,000.00
- Revenue This Year
- OUST $31.39
- TSHA N/A
- Revenue Next Year
- OUST $37.34
- TSHA N/A
- P/E Ratio
- OUST N/A
- TSHA N/A
- Revenue Growth
- OUST 28.04
- TSHA N/A
- 52 Week Low
- OUST $5.84
- TSHA $1.05
- 52 Week High
- OUST $16.88
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- OUST 69.99
- TSHA 60.38
- Support Level
- OUST $9.77
- TSHA $2.44
- Resistance Level
- OUST $10.55
- TSHA $2.95
- Average True Range (ATR)
- OUST 0.78
- TSHA 0.25
- MACD
- OUST 0.12
- TSHA -0.02
- Stochastic Oscillator
- OUST 85.42
- TSHA 51.60
About OUST Ouster Inc.
Ouster Inc is a provider of lidar sensors for the automotive, industrial, robotics, and smart infrastructure industries. Ouster's products include high-resolution scanning and solid-state digital lidar sensors, Velodyne Lidar sensors, and software solutions. The company operates in the Americas, Asia and Pacific, Europe, Middle East, and Africa regions. It derives maximum revenue from Americas.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.